An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.
Transcript:
Rajiv Agarwal, MD, MS: FIDELITY is not a trial, it’s an analysis. It’s a pooled individual level analysis that was prespecified. We prespecified that we would take all the data from FIDELIO-DKD and FIGARO-DKD, and we would pool them to get to the outcomes that we are interested in: the kidney outcomes and the cardiovascular outcomes. Together, we have 13,171 patients from 48 countries in more than 1000 sites who have participated in the 2 trials, as a population randomized to finerenone or a placebo. The follow-up is 3 years, median duration. So we have a lot of years of follow-up in this trial, and we are taking everybody who has an optimized ACE [angiotensin-converting enzyme inhibitor] or ARB [angiotensin receptor blocker]. They have all type 2 diabetes and CKD [chronic kidney disease].
They all have serum potassium of 4.8 mmol/L or less at baseline and run-in. But remember that after the run-in period, we have a 2-week gap between that and randomization. Many patients during that time can have an increase in potassium, and that didn’t matter: they could still get randomized to one of the two treatments. Many times, we had potassium levels of more than 5 mmol/L in the trial. They were still included in the randomization scheme. We excluded patients with symptomatic HFrEF [heart failure with reduced ejection fraction]. We prespecified the cardiovascular composite in the FIDELITY analysis, which was the same as before in the FIGARO trial. There’s a 4-point MACE [major adverse cardiac event] end point, which is CV [cardiovascular] death, nonfatal MI [myocardial infarction], nonfatal stroke, and hospitalization for heart failure.
We also have the kidney composite, which was a 57% decline in eGFR [estimated glomerular filtration rate]; kidney failure, an eGFR of less than 15 and going on dialysis; or death from kidney failure. Those were the 2 outcomes that we fixed, and now we can really analyze people who have stage 1 to stage 4 kidney disease and albuminuria ranging from 30 to 5000 mg/g: nearly all the patients who the nephrologists typically sees. The patients who are not included are the people who have an eGFR of less than 25 and who have no albuminuria in this trial. The strength of this analysis allows you to pool and look at the effects on both the cardiovascular and kidney failure outcomes in this very large population.
Transcript edited for clarity.
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
Dr Madeleine McDowell Discusses How CKD Disparities, Social Challenges Impact Health Care Access
October 4th 2023Madeleine McDowell, MD, hopes these data insights will help change providers' behavior in terms of adopting earlier and more regular screening for chronic kidney disease (CKD).
Read More
Advocating for All Patients With Chronic Kidney Disease
April 26th 2022Chronic kidney disease is the fastest-growing noncontagious disease in the United States. On this episode of Managed Care Cast, we speak with Mike Spigler, vice president of patient support and education for the American Kidney Fund, who is spearheading the Unknown Causes of Kidney Disease Project, which aims to help underserved patients get to the root cause of their kidney disease, while also helping to solve this mystery for a broader patient population.
Listen